molecules of the month

FT-2102 (olutasidenib)

allosteric mutant-selective IDH1 inhibitor

oral, in clinical development

from SBDD of prior mIDH inhibitor

J. Med. Chem. 2020, 63, 1612-1623

FORMA Therapeutics, Watertown, MA

FT-2102 (olutasidenib)
1 min read

FT-2102 (olutsidenib) (FORMA oral allosteric mutant-selective IDH1 inhibitor clinical candidate)

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: